A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2002
12/04/2002	EP1077967B1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
12/04/2002	EP0815124B1 Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
12/04/2002	EP0772451B1 Treatment of type ii diabetes mellitus with amylin agonists
12/04/2002	EP0517817B1 Inhibitors of catalytic antibodies
12/04/2002	CN1383427A Process for preparing N6-substituted deaza-adenosine derivatives
12/04/2002	CN1383426A Obesity inhibitory materials
12/04/2002	CN1382491A Nutritive SOD capsule
12/04/2002	CN1382484A Corn tassel injection and its preparing process
12/04/2002	CN1382483A Hypoglycemic and antihypertensive medicine prepared from edible plant tissue and its preparing process and usage
12/04/2002	CN1382453A Fat reducing cream
12/04/2002	CN1382440A Method and medicine case for treating depression or preventing degeneration of cognitive function
12/04/2002	CN1095466C Soya total flavone, its prepn. method and medical use thereof
12/04/2002	CN1095378C Multifunctional calcium tablet and its prodn. process
12/04/2002	CN1095376C Blood pressure reducing and fat reducing beverage and its prodn. method
12/04/2002	CN1095368C Tea for beautifying face and reducing fat
12/03/2002	US6489478 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
12/03/2002	US6489476 Fructose-1,6-bisphosphatase enzyme inhibitors are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.
12/03/2002	US6489475 Method of producing heterocyclic derivatives
12/03/2002	US6489366 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
12/03/2002	US6489349 Treating an autoimmune disorder with an alkylamine substituted pyridine
12/03/2002	US6489347 Process
12/03/2002	US6489344 For treatment diabetes in a human or animal subject
12/03/2002	US6489328 Heterocyclic compounds useful as inhibitors of tyrosine kinases
12/03/2002	US6489323 Inhibiting no production from l-arginine, as seen in disease states such as arthritis and systemic hypotension associated with septic and/or toxic shock
12/03/2002	US6489295 Antagonists of intestinotrophic GLP-2 peptides
12/03/2002	CA2213198C Gene therapy by anti-tgf-b agents
12/03/2002	CA2116478C Prolonged delivery of peptides
12/03/2002	CA2116120C Peptides having growth hormone releasing activity
12/03/2002	CA2074933C Thiazole derivatives as active superoxide radical inhibitors
12/03/2002	CA2073856C Glp-1 analogs useful for diabetes treatment
12/03/2002	CA2065644C Pyrazolopyridine compound and processes for preparation thereof
11/2002
11/30/2002	CA2388287A1 Therapies for the prevention and treatment of diabetes and obesity
11/29/2002	WO2001093899A1 PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS
11/29/2002	CA2410918A1 Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095034A2 A retinoic acid metabolizing cytochrome p450
11/28/2002	WO2002095020A1 A gene and uses therefor
11/28/2002	WO2002095012A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002095006A2 Muscle-specific expression vectors
11/28/2002	WO2002094997A2 Transcriptional regulation of target genes
11/28/2002	WO2002094990A2 Receptors and membrane-associated proteins
11/28/2002	WO2002094856A2 Gpe analogs and peptidomimetics
11/28/2002	WO2002094833A1 Novel pyrrole derivatives as pharmaceutical agents
11/28/2002	WO2002094825A1 Novel spiropiperidine derivative
11/28/2002	WO2002094821A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	WO2002094799A2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/28/2002	WO2002094795A1 4-aminopyrimidine derivatives
11/28/2002	WO2002094790A1 Fused heterocyclic compound and medicinal use thereof
11/28/2002	WO2002094789A1 Quinoline derivatives as ligands for the neuropeptide y receptor
11/28/2002	WO2002094780A2 Kinases and phosphatases
11/28/2002	WO2002094754A1 Vitamin d analogues
11/28/2002	WO2002094344A2 Method and apparatus for removal of insulin binding proteins (ibp) from biological fluids
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094322A2 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
11/28/2002	WO2002094299A1 Medicinal plant extracts used in the treatment of diabetic diseases
11/28/2002	WO2002094285A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/28/2002	WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002	WO2002094262A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002	WO2002094255A1 Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
11/28/2002	WO2002094247A2 Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
11/28/2002	WO2002094221A1 Emulsion and dispersion formulations and method
11/28/2002	WO2002094203A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002	WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002	WO2002094200A2 Pulmonary administration of chemically modified insulin
11/28/2002	WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002	WO2002094178A2 Treatment of renal fibrosis
11/28/2002	WO2002085897A8 Heterocyclic compounds for aging-related and diabetic vascular complications
11/28/2002	WO2002085377A8 Method for lowering serum glucose
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002078641A3 Pyrrolidine sulfonamides
11/28/2002	WO2002078616A3 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
11/28/2002	WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002070532A3 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
11/28/2002	WO2002068652A9 Nov-x proteins and nucleic acids encoding same
11/28/2002	WO2002062777A3 Amino ceramide-like compounds and therapeutic methods of use
11/28/2002	WO2002048106A3 Isoindolin-1-one glucokinase activators
11/28/2002	WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002	WO2002039997A3 Ace-2 modulating compounds and use thereof
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001091587A9 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020178459 Genetically engineered mammal for use in the treatment of muscle and liver disorders
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177610 Hypolipidemics; treating obesity and disorders of lipid metabolism
11/28/2002	US20020177609 Fatty alcohol drug conjugates
11/28/2002	US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002	US20020177602 Antidiabetic formulation and method
11/28/2002	US20020177600 Two or more ligand moieties covalently linked together by one or more linking groups enabling binding to multiple binding sites; increased efficacy, selectivity and duration; anti-proliferative and anticarcinogenic
11/28/2002	US20020177596 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
11/28/2002	US20020177591 Central nervous system (CNS); diazabicyclo compounds such as 1,4-Diaza-bicyclo(3.2.2)nonane-4-carboxylic acid, 4-cyclohexyl-phenyl ester; CNS-penetrant alpha 7 nicotinic receptor agonist
11/28/2002	US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002	US20020177586 Method for treating fibrotic diseases or other indications ID

1 ... 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 ... 1298